Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Pulmonary Arterial Hypertension Market Revenue Growth On Track For A 8.5% CAGR Through 2030
The pulmonary arterial hypertension market size has demonstrated substantial growth in recent years. It is projected to expand from $9.15 billion in 2025 to $9.94 billion in 2026, achieving a compound annual growth rate (CAGR) of 8.6%. This historical expansion can be attributed to the rising prevalence of pulmonary arterial hypertension, limited early diagnosis capabilities, high unmet medical needs, availability of conventional drugs, and growing awareness among healthcare professionals.
The pulmonary arterial hypertension market is anticipated to experience substantial expansion over the upcoming years. This market is projected to reach $13.75 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 8.5%. The projected growth during this period is driven by factors such as the development of novel therapies, the expansion of telemedicine services, increasing government healthcare initiatives, the rising adoption of combination therapies, and the growth in specialized treatment centers. Concurrently, key trends expected in the forecast period include personalized pulmonary hypertension therapies, advanced drug delivery systems, the continued development of combination therapy, the widespread use of telehealth and remote patient monitoring, and the establishment of emerging regional treatment centers.
Get A Free Sample Report With In-Depth Market Insights:
Pulmonary Arterial Hypertension Market Growth Momentum: What Factors Are Shaping Demand?
The increasing number of clinical trials for drug development is anticipated to stimulate the expansion of the pulmonary arterial hypertension market going forward. Clinical trials for drug development are research endeavors performed to assess the safety, effectiveness, and potential adverse reactions of novel drugs or therapies in human subjects. For pulmonary arterial hypertension, these trials can result in the creation of newer and more potent treatments, thereby enhancing patient quality of life, improving safety and efficacy, providing earlier access, and aiding in the discovery of cost-effective therapies. As an illustration, in May 2023, data from Xtalks, a Canada-based company specializing in providing life science webinars and virtual events, indicated that 452,604 clinical studies were registered on ClinicalTrials.gov as of May 17, 2023. Among the registered total, 64,838 studies are actively looking for participants, reflecting an overall increase of 365,000 registered trials in 2021. Consequently, the uptick in clinical trials for drug development is fueling the growth of the pulmonary arterial hypertension market.
Pulmonary Arterial Hypertension Market Segment Landscape: Which Areas Lead Development?
The pulmonary arterial hypertension market covered in this report is segmented –
1) By Drug Class: Endothelin Receptor Antagonists (ERAs), PDE-5 Inhibitors, Prostacyclin and Prostacyclin Analogs, SGC Stimulators
2) By Route Of Administration: Oral, Intravenous Or subcutaneous, Inhalational
3) By Distribution channel: Retail, Online
Subsegments:
1) By Endothelin Receptor Antagonists (ERAs): Bosentan, Ambrisentan, Macitentan
2) By PDE-5 Inhibitors: Sildenafil, Tadalafil
3) By Prostacyclin And Prostacyclin Analogs: Epoprostenol, Treprostinil, Iloprost
4) By SGC Stimulators: Riociguat, Vericiguat
Pulmonary Arterial Hypertension Market Trends Redefining Industry Growth
Major companies in the pulmonary arterial hypertension market are creating advanced products, such as OPSYNVI, to deliver enhanced treatment options that boost patient outcomes and the quality of life for individuals suffering from this serious condition. For instance, in March 2024, Johnson & Johnson, a US-based multinational company specializing in pharmaceuticals, biotechnology, and medical technologies, introduced OPSYNVI for the chronic treatment of adults with pulmonary arterial hypertension. OPSYNVI is suitable for patients with pulmonary arterial hypertension (PAH) who are either commencing treatment or are already receiving an endothelin receptor antagonist (ERA) or PDE5 inhibitor, or both. It is also applicable for those on stable doses of macitentan 10 mg and tadalafil 40 mg, given as separate tablets.
Pulmonary Arterial Hypertension Market Industry Leaders And Competitive Landscape
Major companies operating in the pulmonary arterial hypertension market are United Therapeutics Corporation, Acceleron Pharma Inc., Actelion Pharmaceuticals US Inc., Bayer AG, Eli Lilly and Company, Gilead Sciences Inc., GlaxoSmithKline plc, Johnson & Johnson, Liquidia Technologies Inc., Lupin Pharmaceuticals Inc., Natco Pharma Ltd., Pfizer Inc., Sandoz AG, Teva Pharmaceutical Industries Ltd., Zydus Pharmaceutical USA Inc., Merck KGaA, Novartis International AG, Bristol-Myers Squibb Company, AstraZeneca plc, Daiichi Sankyo Company Limited
View The Full Pulmonary Arterial Hypertension Market Report:
Pulmonary Arterial Hypertension Market Regional Analysis And Leading Geography
North America was the largest region in the pulmonary arterial hypertension market in 2025. The regions covered in the pulmonary arterial hypertension market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
